Hot line:010-61006450
ENAbout Us
Stock(600222)
Leadingpharm (stock code: 600222) was established in 2005 with a registered capital of 91.554 million yuan. It is a high-tech enterprise providing pharmacy pre-clinical research, clinical CRO and CDMO services worldwide. It has been rated as "China’s Top 10 Pharmaceutical R&D Enterprises " for many years (ranked first in 2019). The company is headquartered in Beijing Zhongguancun High-tech Park and has established new drug screening and testing platform, drug evaluation platform (animal room, certified by GLP, AAALAC, CNAS), large molecule pilot and large-scale production platform, small molecule CMC research and production platform, cell technology platform and clinical CRO platform in Zhengzhou Linkong Biological Park. The six platforms comply with international standards (FDA, EMA and NMPAGMP) , forming " Leadingpharm CXO" whole industry chain service system. The combination of imitation and creation, driven by dual engines, can provide customers with diversified services throughout the pharmaceutical research and development.
Services
-
New drug screening and testing
high-throughput drug screening, active compound discovery, target verification, lead compound optimization, preclinical drug candidate selection, etc
-
Drug evaluation
drug discovery, chemical synthesis, biological analysis, PK/PD model fitting, macromolecular drugs, clinical declaration, toxicology, pharmacokinetics, etc
-
API and preparation CMC
API synthesis process, formulation process , drug quality research and method verification, impurity customization, special substance testing, etc
-
Small molecule drugs CDMO
insoluble drug solution, pilot test of oral and injection dosage forms (tablets, capsules, granules, small volume injections, etc.)
-
Macromolecular drugs CDMO
stable cell screening, pilot fermentation process, large-scale culture process and macromolecule purification process development, antibody drugs, recombinant protein drugs, etc
-
Cell and gene therapy drugs CDMO
full-process CDMO services for cell and gene therapy drugs (plasmid, virus, cell drug form)-small test, pilot test, pre-clinical research, etc
-
Clinical CRO
phase I~IV clinical trials of innovative drugs and generic drugs, BE trials of generic drugs, pharmacokinetics (PK/PD) clinical studies, etc
-
Import and export registration
introduction of characteristic varieties (agent registration and localized production), China-U.S. registration on API and Preparation, etc
- Shenyang
- Dalian
- Hangzhou
- Beijing
- Shijiazhuang
- Zhengzhou
- Wuhan
- Changsha
- Guangzhou
- Taiyuan
- Guizhou
News
- Company News |
- Pharm News
The EG-017Ⅱ Phase II Program Seminar and Launching Meeting was successfully held
Recently, the EG-017 Phase II clinical trial program seminar and kick-off meeting jointly conducted by Beijing New Leading Zhengzhou Deep Blue Sea and Ningbo Xijian Pharmaceutical Technology Co., Ltd. was successfully held in the form of offline main venue (Beijing)+online video conference.
Phase III clinical trial scheme discussion of recombinant human erythropoietin -Fc fusion protein for injection was successfully held
Recently, the Phase III clinical trial scheme discussion of recombinant human erythropoietin -Fc fusion protein for injection (hereinafter referred to as "rhEPO-Fc fusion protein") jointly conducted by Beijing New Leading Zhengzhou Deep Blue Sea and Shandong Danhong Pharmaceutical (a wholly-owned subsidiary of Buchang Pharmaceutical) was successfully held in the form of offline main venue (Beijing)+online video conference.
Drug R&D and Transformation CXO Whole Industry Chain Innovation The service forum is a complete success, and the new leadership opens a new era of CXO in an all-round way!
On September 27th, the "Sub-Forum 5 of the Second Zhengzhou International Biomedical Development Summit Forum-CXO Innovation Service Forum of Pharmaceutical R&D and Transformation Industry Chain", jointly sponsored by the Pharmaceutical Chamber of Commerce of All-China Federation of Industry and Commerce, R&D and Transformation Service Professional Committee of China Food and Drug Enterprise Quality and Safety Promotion Association, and Shenzhen Shenlanhai, a new leader in Beijing, was a complete success! Experts, scholars and enterprise representatives gathered together to discuss the development direction of CXO's innovative service in the whole industrial chain, and help the innovation and development of China's biomedical industry.
-
The 2nd Zhengzhou International Biomedical Development Summit Forum was grandly opened. Mr. Tao Xinhua, the new leading chairman, was surprised to interpret the new leading CXO ecosystem!
2020-09-28 -
Strategic Cooperation | | New Leading and School of Chemistry and Chemical Engineering, Beijing Institute of Technology Signing ceremony of strategic cooperation
2020-09-22 -
Charity for poverty alleviation, Leadingpharm Medicine donations to help Gansu Gannan Prefecture overcome poverty!
2020-09-08
.png)
010-61006450
Address：
Marketing Department：
Leadingpharm
Pharm News
010-61006450
